Compare GIPR & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIPR | LYRA |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 5.6M |
| IPO Year | 2021 | 2020 |
| Metric | GIPR | LYRA |
|---|---|---|
| Price | $0.75 | $2.32 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 68.0K | ★ 120.1K |
| Earning Date | 11-17-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,953,920.00 | $600,000.00 |
| Revenue This Year | $1.12 | N/A |
| Revenue Next Year | $0.52 | $93.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.63 | $1.63 |
| 52 Week High | $2.06 | $37.50 |
| Indicator | GIPR | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 44.99 | 34.63 |
| Support Level | $0.71 | $1.63 |
| Resistance Level | $0.86 | $2.58 |
| Average True Range (ATR) | 0.06 | 0.27 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 47.76 | 25.54 |
Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.